Free Trial

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

$31.06
-1.30 (-4.02%)
(As of 06/12/2024 ET)

Arcturus Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 7 Analyst Ratings

Consensus Price Target

$64.86
108.81% Upside
High Forecast$90.00
Average Forecast$64.86
Low Forecast$45.00
TypeCurrent Forecast
6/13/23 to 6/12/24
1 Month Ago
5/14/23 to 5/13/24
3 Months Ago
3/15/23 to 3/14/24
1 Year Ago
6/13/22 to 6/13/23
Consensus Rating
Buy
Buy
Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$64.86$64.86$56.43$32.25
Forecasted Upside108.81% Upside104.69% Upside89.01% Upside52.03% Upside
Get Arcturus Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.

ARCT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Arcturus Therapeutics Stock vs. The Competition

TypeArcturus TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.70
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside108.81% Upside811.78% Upside11.07% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Forecasts and Stock Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/23/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
5/10/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$87.00 ➝ $86.00+210.81%
3/20/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$60.00+77.73%
2/8/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$40.00 ➝ $48.00+23.39%
8/22/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Stavropoulos
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$54.00+69.81%
7/17/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$35.00 ➝ $45.00+26.98%
7/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
11/10/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSell$8.00 ➝ $14.00-31.34%
11/10/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$18.00-14.65%
11/2/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight$16.00 ➝ $25.00+36.76%
8/10/2022Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Raja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
8/10/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeMarket Perform ➝ Underperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:05 PM ET.

ARCT Frequently Asked Questions

What is Arcturus Therapeutics's stock forecast and purchase recommendation?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Arcturus Therapeutics is $64.86, with a high forecast of $90.00 and a low forecast of $45.00. The consensus rating for Arcturus Therapeutics stock is Buy based on the current 7 buy ratings for ARCT. Learn more on ARCT's analyst rating history.

Do Wall Street analysts like Arcturus Therapeutics more than its competitors?

Analysts like Arcturus Therapeutics more than other "medical" companies. The consensus rating for Arcturus Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ARCT compares to other companies.

Does Arcturus Therapeutics's stock price have much upside?

According to analysts, Arcturus Therapeutics's stock has a predicted upside of 104.69% based on their 12-month stock forecasts.

What analysts cover Arcturus Therapeutics?

Arcturus Therapeutics has been rated by research analysts at Canaccord Genuity Group, HC Wainwright, and William Blair in the past 90 days.


Stock Forecasts and Research Tools

This page (NASDAQ:ARCT) was last updated on 6/12/2024 by MarketBeat.com Staff

From Our Partners